双靶点磷酸二酯酶3/4抑制剂Ensifentrine对中重度COPD急性加重率与风险的影响
该研究为ENHANCE-1和ENHANCE-2两项3期试验的预设汇总分析,纳入975例接受Ensifentrine 3 mg每日两次治疗和574例接受安慰剂的中重度COPD患者,治疗24周。
要点
- Ensifentrine降低中重度COPD患者中重度急性加重率与首次加重风险。
- 获益在年龄、性别、种族、背景维持治疗、嗜酸性粒细胞计数等亚组中基本一致。
- Ensifentrine在从GOLD B组向E组转变上显示数值上的延迟。
核心结论
- Ensifentrine可降低中重度COPD患者急性加重率并延长首次急性加重时间,且在广泛临床相关亚组中一致。
研究设计与样本
- ENHANCE-1(NCT04535986)与ENHANCE-2(NCT04542057)两项3期试验的预设汇总分析。
- 纳入975例接受Ensifentrine 3 mg每日两次治疗和574例接受安慰剂的患者,治疗24周。
- 患者为40至80岁有症状的中重度COPD患者;62%联用长效抗胆碱能药或长效β2受体激动剂,18%联用吸入糖皮质激素。
主要发现
- 亚组分析显示年龄、性别、种族、背景维持治疗、慢性支气管炎、嗜酸性粒细胞计数、COPD严重度和加重史等亚组中加重率与风险降低基本一致。
- 与安慰剂相比,Ensifentrine在从频繁加重者(GOLD E组)向非频繁加重者(GOLD B组)转变上显示数值上的延迟。
临床怎么用
- 对于中重度COPD患者,可考虑使用Ensifentrine以降低急性加重率和风险。
- Ensifentrine的获益不受年龄、性别、种族、背景维持治疗、嗜酸性粒细胞计数、COPD严重度及加重史等常见临床特征明显影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Exacerbations in COPD can be life-threatening and can lead to irreversible declines in lung function and quality of life. Medications that reduce exacerbation burden are an unmet need, because exacerbations put patients at risk of more exacerbations and decrease quality of life. Ensifentrine is a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 with demonstrated nonsteroidal antiinflammatory activity and bronchodilatory effects. RESEARCH QUESTION: Does ensifentrine reduce the rate or risk of COPD exacerbations? STUDY DESIGN AND METHODS: A prespecified, pooled analysis of the phase 3 clinical trials Ensifentrine as a Novel Inhaled Nebulized COPD Therapy (ENHANCE)-1 (ClinicalTrials.gov Identifier: NCT04535986) and ENHANCE-2 (ClinicalTrials.gov Identifier: NCT04542057) was conducted to assess the effect of ensifentrine on exacerbation rate and risk (time to first exacerbation). The trials included symptomatic patients aged 40 to 80 years with moderate to severe COPD who received 3 mg twice-daily ensifentrine over 24 weeks or placebo. Subgroup analyses and frequent exacerbator transition risk assessment were conducted post hoc. RESULTS: In total, 975 patients treated with ensifentrine and 574 patients who received placebo were included in the pooled analysis, including 62% of patients receiving concomitant long-acting muscarinic antagonist or long-acting β2-agonist therapy and 18% receiving concomitant inhaled corticosteroid therapy. Ensifentrine was associated with significant reductions in the rate (rate ratio, 0.59; 95% CI, 0.43-0.80; P < .001) and risk (hazard ratio, 0.59; 95% CI, 0.44-0.81; P < .001) of moderate to severe exacerbations compared with placebo. Reductions in the rate and risk of exacerbations generally were consistent across patient subgroups, including age, sex, race, background maintenance medication use, chronic bronchitis, eosinophil count, COPD severity, and exacerbation history. Ensifentrine was associated with a numerical delay in transitioning from an infrequent exacerbator (Global Initiative for Chronic Obstructive Lung Disease group B) to a frequent exacerbator (Global Initiative for Chronic Obstructive Lung Disease group E) compared with placebo. INTERPRETATION: Ensifentrine reduced the rate of exacerbations and increased the time to first exacerbation among patients with COPD across a broad range of clinically relevant subgroups.
引用
- Sciurba, Christenson, Rheault, et al. Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD. Chest. 2024. PMID: 39197510. doi:10.1016/j.chest.2024.07.168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。